46
COVID-19 reinfection in Afghanistan: A descriptive analysis of data from DHIS2, 2022
46
10.60141/AJID/V.2.I.1.4
COVID-19 reinfection in Afghanistan: A descriptive analysis of data from DHIS2, 2022
<p><strong>Background:</strong> Despite millions of COVID-19 infections worldwide since the beginning of the pandemic, relatively few confirmed cases of COVID-19 reinfection have been reported. In Afghanistan, COVID-19 undetected cases are more than detected cases. This study aims to describe the burden of COVID-19 reinfection cases in Afghanistan, along with the epidemiological and demographical patterns.</p>
<p><strong>Methods:</strong> A descriptive study of national-wide secondary data on COVID-19 reinfection cases was carried out from January to June 2022. Data were extracted from the District Health Information Software 2 (DHIS2) and managed and analyzed using Microsoft Excel and Epi Info V.7.2.1.</p>
<p><strong>Results:</strong> In 2022, 79 reinfection cases of COVID-19 were reported, with males being more affected than females. The mean age of re-infected patients was 39, with most from Wardak province. Most cases occurred within six months after the primary infection. Cough was more prevalent among reinfected cases. Only 26 patients had taken two doses of the vaccine, while 44 (55.70%) had not received it. Out of all cases, 44 (55.70%) were recovered and 5 (6.85%) died.</p>
<p><strong>Conclusion: </strong> The COVID-19 reinfection rate is very low in Afghanistan, which was common in males since other cases might be unreported. Coughing was more common among reinfection patients. Relying on the results, vaccination and awareness-raising may play a protective role in reinfection; hence, enhancement of vaccination and taking preventive measures are recommended to prevent further reinfection.</p>
https://creativecommons.org/licenses/by/4.0
2024
COVID-19
Reinfection
Afghanistan
DHIS2
Razia
Soltany
Afghanistan National Public Health Institute (ANPHI|)
AF
raziasoltany@gmail.com
https://orcid.org/0009-0001-6553-8165
<p>BSPH, FETP Alumnus, Afghanistan National Public Health Institute (ANPHI|), Kabul, Afghanistan.</p>
Mir Salamuddin
Hakim
Afghanistan Field Epidemiology Training Program
AF
raziasoltany@gmail.com
https://orcid.org/0000-0001-9494-6507
<p>Afghanistan Field Epidemiology Training Program, Kabul, Afghanistan.</p>
Khwaja Mir Islam
Saeed
Afghanistan Field Epidemiology Training Program
AF
raziasoltany@gmail.com
https://orcid.org/0000-0002-8799-4604
<p>Afghanistan Field Epidemiology Training Program, Kabul, Afghanistan.</p>
Shoaib
Naeemi
Afghanistan Field Epidemiology Training Program
AF
raziasoltany@gmail.com
https://orcid.org/0000-0002-8094-601X
<p>Afghanistan Field Epidemiology Training Program, Kabul, Afghanistan.</p>
60
PDF
0
Kesheh, M.M. et al. (2021) “An overview on the seven pathogenic human coronaviruses,” Reviews in Medical Virology, 32(2). Available at: https://doi.org/10.1002/rmv.2282.
Coronavirus disease (COVID-19) pandemic [Internet]. Who.int. 2022 [cited 23 July 2022]. Available from: https://www.who.int/europe/ emergencies/situations/COVID-19
Coronavirus cases: (no date) Worldometer. Available at: https://www.worldometers.info/coronavirus/ (Accessed: March 20, 2023).
Ritchie H, Mathieu E, Rodés-Guirao L, Appel C, Giattino C, Ortiz-Ospina E Et al. Coronavirus Pandemic (COVID-19) [Internet]. Our World in Data. 2022 [cited 23 July 2022]. Available from: https://ourworldindata.org/covid-vaccinations
CDC. Coronavirus Disease 2019 (COVID-19) [Internet]. Centers for Disease Control and Prevention. 2020. Available from: https://www.cdc.gov/coronavirus/2019-ncov/your-health/reinfection.html
He, Z., et al., Seroprevalence and humoral immune durability of anti-SARS-CoV-2 antibodies in Wuhan, China: a longitudinal, population-level, cross-sectional study. Lancet, 2021. 397(10279): p. 1075-1084
Gundlapalli, A.V., et al., SARS-CoV-2 Serologic Assay Needs for the Next Phase of the US COVID-19 Pandemic Response. Open Forum Infectious Diseases, 2020. 8(1)
Cavanaugh AM, Spicer KB, Thoroughman D, Glick C, Winter K. Reduced risk of reinfection with SARS-CoV-2 after COVID-19 vaccination—Kentucky, May–June 2021. MMWR Morb Mortal Wkly Rep 2021; 70:10813. https:// doi.org/10.15585/mmwr.mm7032e1externalicon PMID:34383732external icon
Grant R, Charmet T, Schaeffer L, et al. Impact of SARS-CoV-2 Delta variant on incubation, transmission settings and vaccine effectiveness: Results from a nationwide case-control study in France. Lancet Reg Health Eur 2021. Epub November26,2021. https://doi.org/10.1016/j.lanepe. 2021.100278external icon
[Internet]. 2022 [cited 27 July 2022]. Available from:https://newsinhealth.nih.gov/2021/04/antibodies-protect-against-COVID-19-reinfection
Murchu E, Byrne P, Carty PG, De Gascun C, Keogan M, O'Neill M, Harrington P, Ryan M. Quantifying the risk of SARS-CoV-2 reinfection over time. Rev Med Virol. 2022 Jan;32(1):e2260. doi: 10.1002/rmv.2260. Epub 2021 May 27. PMID: 34043841; PMCID: PMC8209951.
[Internet]. 2022 [cited 28 July 2022]. Available from: https://ndc.services.cdc. gov/case-definitions/coronavirus-disease-2019 2021/?utm_ source=substack&utm_medium=email
Michlmayr D, Andersen M, Meaidi M, Irshad I, de Sousa L, Fonager J et al. SARS-CoV-2 Reinfections in Denmark Confirmed by Whole Genome Sequencing. SSRN Electronic Journal. 2022; (Sustained Positivity and Reinfection with SARS-CoV-2 in Children: Does Quarantine/Isolation Period Need Reconsideration in a Pediatric Population?)
Stegger, M. et al. (2022) Occurrence and significance of Omicron Ba.1 infection followed by BA.2 reinfections, medRxiv. Cold Spring Harbor Laboratory Press. Available at: https://www.medrxiv.org/content/10.1101/2022.02.19.22271112v1 (Accessed: March 19, 2023).
Roskosky M, Borah B, DeJonge P, Donovan C, Blevins L, Lafferty A et al. Notes from the Field: SARS-CoV-2 Omicron Variant Infection in 10 Persons Within 90 Days of Previous SARS-CoV-2 Delta Variant Infection — Four States, October 2021–January 2022. MMWR Morbidity and Mortality Weekly Report. 2022;71(14):524-526.
Coronavirus.data.gov.uk. 2022. [online] Available at:<https://coronavirus.data.gov.uk/details/cases?areaType=nation&areaName=England&utm_source=substack&utm_medium=email> [Accessed 29 July 2022].
Mensah A, Lacy J, Stowe J, Seghezzo G, Sachdeva R, Simmons R et al. Disease severity during SARS-COV-2 reinfection: a nationwide study. Journal of Infection. 2022;84(4):542-550.
Abu-Raddad L, Chemaitelly H, Bertollini R. Severity of SARS-CoV-2 Reinfections as Compared with Primary Infections. New England Journal of Medicine. 2021;385(26):2487-2489.
Ons.gov.uk. 2022. Coronavirus (COVID-19) Infection Survey technical article: analysis of reinfections of COVID-19 - Office for National Statistics. [online] Available at: <https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/articles/coronaviruscovid19infectionsurveytechnicalarticleanalysisofreinfectionsofcovid19/june2021?utm_source=substack&utm_medium=email> [Accessed 29 July 2022].
Rahman S, Rahman MM, Miah M, Begum MN, Sarmin M, Mahfuz M, Hossain ME, Rahman MZ, Chisti MJ, Ahmed T, Arifeen SE, Rahman M. COVID-19 reinfections among naturally infected and vaccinated individuals. Sci Rep. 2022 Jan 26;12(1):1438. doi: 10.1038/s41598-022-05325-5. PMID: 35082344; PMCID: PMC8792012
Medić S, Anastassopoulou C, Lozanov-Crvenković Z, Vuković V, Dragnić N, Petrović V et al. Risk and severity of SARS-CoV-2 reinfections during 2020–2022 in Vojvodina, Serbia: A population-level observational study. The Lancet Regional Health - Europe. 2022; 20:100453.
Wang J, Kaperak C, Sato T, Sakuraba A. COVID-19 reinfection: a rapid systematic review of case reports and case series. Journal of Investigative Medicine. 2021;69(6):1253-1255.
Azimi, M., Yadgari, M.Y. and Atiq, M.A. (2023) “Acceptance and hesitancy toward the covid-19 vaccine among medical students in Kabul, Afghanistan,” Infection and Drug Resistance, Volume 16, pp. 457–461. Available at: https://doi.org/10.2147/idr.s389582.
Falahi S, Kenarkoohi A. Sex and gender differences in the outcome of patients with COVID‐19. J Med Virol. 2021;93(1):151‐152. [PMC free article] [PubMed] [Google Scholar] [Ref list].
Cavanaugh A, Spicer K, Thoroughman D, Glick C, Winter K. Reduced Risk of Reinfection with SARS-CoV-2 After COVID-19 Vaccination — Kentucky, May–June 2021. MMWR Morbidity and Mortality Weekly Report. 2021;70(32):1081-1083.
2
1
2024
Second Volume, First issue, january 2024
25-32